"Drug Approval" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug.
| Descriptor ID |
D017277
|
| MeSH Number(s) |
E05.337.300 I01.880.604.605.250.250
|
| Concept/Terms |
Drug Approval- Drug Approval
- Approval, Drug
- Approvals, Drug
- Drug Approvals
- Food and Drug Administration Drug Approval
Drug Approval Process- Drug Approval Process
- Approval Process, Drug
- Approval Processes, Drug
- Drug Approval Processes
- Process, Drug Approval
- Processes, Drug Approval
New Drug Approval- New Drug Approval
- Approval, New Drug
- Approvals, New Drug
- Drug Approval, New
- Drug Approvals, New
- New Drug Approvals
|
Below are MeSH descriptors whose meaning is more general than "Drug Approval".
Below are MeSH descriptors whose meaning is more specific than "Drug Approval".
This graph shows the total number of publications written about "Drug Approval" by people in this website by year, and whether "Drug Approval" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 3 | 5 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 3 | 3 | 6 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Approval" by people in Profiles.
-
Trends in complexity of single-agent and combination therapies for solid tumor cancers approved by the US Food and Drug Administration. Oncologist. 2025 Mar 10; 30(3).
-
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
-
A Look Into the Future: Are We Ready for an Approved Therapy in Celiac Disease? Gastroenterology. 2024 Jun; 167(1):183-193.
-
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 11 01; 9(11):1489-1490.
-
Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval. J Ocul Pharmacol Ther. 2023 10; 39(8):572-582.
-
Making the Case for Accelerated Withdrawal of Aducanumab. J Alzheimers Dis. 2022; 87(3):1003-1007.
-
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clin Pharmacol Ther. 2021 07; 110(1):29-31.
-
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021 01; 589(7841):270-275.
-
From COVID-19 research to vaccine application: why might it take 17?months not 17?years and what are the wider lessons? Health Res Policy Syst. 2020 Jun 08; 18(1):61.
-
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1).